Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally.

Y-mAbs is a commercial-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. We have a broad and advanced product pipeline, including pivotal-stage product candidates against a range of targets.

YmAbs_Logo_RGB.jpg. Format JPEG. Source Y-mAbs Therapeutics, Inc. Downloads. Original Large Medium Small About Us. GlobeNewswire is one of the world's largest newswire distribution networks ...

Y-mAbs Connect is a patient support program that provides information about access, insurance, financial support, and other resource programs for qualifying patients. Y-mAbs Connect may be able to help qualified patients get started on a prescribed Y-mAbs medication.

The logo for Y-mAbs Therapeutics, Inc. is trademark of Y-mAbs Therapeutics, Inc. For more information about Danyelza, please visit danyelza.com This website uses cookies to improve your experience.

Y-mAbs is a commercial stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer.

Feb 20, 2025 · Y-mAbs Therapeutics Inc. (Y-mAbs) is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer based on a range of technologies licensed from Memorial Sloan Kettering Cancer Center.

Y-mAbs is a commercial-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer.

About the Y-mAbs development pipeline of therapies. Y-mAbs Therapeutics has an expanding portfolio that features accelerated FDA approval for naxitamab and investigational GD2-SADA and CD38-SADA.

Logo is a canadian trademark and brand of Y-mAbs Therapeutics, Inc., New York, NY 10169,UNITED STATES. This trademark was filed to the Canadian Intellectual Property Office on Thursday, June 25, 2020.